Aims: Lanthanum carbonate is used as an alternative to calcium-based phosphate binders to manage hyperphosphataemia in patients with renal failure. The deposition of lanthanum within gastroduodenal mucosa of patients treated with the medication has been described, but given the relative novelty of this entity, the histiocytic deposits in the gastroduodenal mucosa can be confused with a variety of other processes, including infections and other drug-induced forms of injury. Methods and results: We describe five cases of lanthanum phosphate deposition in upper gastrointestinal (GI) tract biopsies. Three cases were confirmed with scanning electron microscopy and energy dispersive X-ray analysis, including one unique patient, status post-renal transplant for polycystic kidney disease, who had last taken lanthanum 7 years prior to biopsy. Conclusion: Lanthanum deposition in the upper GI tract is a mimic of other drug-related forms of GI injury, including iron pill-related gastropathy. The key to making this diagnosis is a thorough drug history and awareness of the histological features.
Introduction
In 2004, lanthanum carbonate, an orally administrated non-calcium-based phosphate-binder, was approved by the United States' Food and Drug Administration (FDA) for treatment of hyperphosphataemia in patients on dialysis. Lanthanum carbonate has been reported to be effective with decreased pill burden, fewer adverse effects and a potentially decreased risk of mortality compared to calcium-based phosphate binders. 1 Lanthanum carbonate therapy is not, however, without complications. Various adverse gastrointestinal (GI) effects have been described in patients on lanthanum carbonate therapy, particularly dysphagia, nausea, vomiting and reflux. [1] [2] [3] Endoscopic findings include the presence of non-specific gastritis, gastric erosion, gastric ulceration, gastric polyps and duodenal ulceration. [4] [5] [6] [7] [8] [9] Biopsies taken from gastric and duodenal lesions have shown accumulations of histiocytes filled with granular material within the lamina propria. These deposits have been characterized as lanthanum phosphate by scanning electron microscopy and energy dispersive X-ray analysis. [4] [5] [6] [7] [8] [9] [10] Despite several reports of deposition of lanthanum in tissue, the histopathologial features associated with lanthanum carbonate are not well recognized. Herein, we describe our experience with five patients with GI changes secondary to lanthanum carbonate therapy, including one with only a remote history of lanthanum carbonate treatment. Scanning electron microscopy and energy dispersive X-ray spectroscopy (EDS) were used to confirm the presence of lanthanum and phosphorus in these deposits in three cases. The study was approved by the Massachusetts General Hospital IRB committee (16 November 2015 . Informed, written consent was waived. The research was performed in accordance with the Declaration of Helsinki.
Materials and methods
Three upper GI tract biopsies that had accumulation of histiocytes with coarsely granular, amphophilic material within the lamina propria were seen in routine surgical pathology biopsy material at Massachusetts General Hospital, Boston, Massachusetts over an interval of 2 months. Two cases were seen in routine biopsy material at the Beth Israel Deaconess Medical Center, Boston, Massachusetts during the same period.
To confirm the presence of lanthanum in the deposits, the freshly cut surface of paraffin blocks of three cases (including one patient no longer taking lanthanum) were examined directly with a scanning electron microscope (SEM), using the variable pressure system of the FEI Company (previously ASPEX) SEM, as described previously. 11 The operating conditions were 20 keV accelerating voltage, 15-16-mm working distance, 0.15 torr pressure in the specimen chamber. Back-scattered electron imaging revealed relatively high atomic number inorganic materials in a low atomic number organic matrix (tissue). The EDS spectra collected from individual features of micrometer dimensions were compared with standard reference spectra of chemical elements, thus demonstrating the elemental composition of each feature.
In order to determine if other cases had been missed, a computer search for lanthanum, histiocytosis, gastric mucosal calcinosis, medication-induced gastritis and iron therapy-related gastritis was performed and all cases diagnosed at Massachusetts General Hospital during a 2-year period, from July 2013 to July 2015, were retrieved and reviewed. No additional cases were found, although this may reflect the difficulty of uncovering cases using language searches.
Results
The clinical features are summarized in Table 1 . The three men and two women ranged in age from 29 to 66 years (mean 53 years). Four patients had endstage renal disease at the time of biopsy. Three patients were on peritoneal dialysis and one was on haemodialysis. Total daily doses of lanthanum carbonate varied from 3000 to 6000 mg per day. One patient (case 5) had received a successful deceased donor renal transplant 7 years previously and had not taken lanthanum carbonate since the transplant. The most common GI symptoms that lead to upper endoscopy were nausea and reflux. Endoscopic abnormalities were found most often in the gastric antrum, and included erythematous mucosal changes.
Lanthanum deposits were found in three gastric antral biopsies, two gastric fundic biopsies and one duodenal biopsy. One patient had both duodenal and antral deposits, and this patient also had biopsies of an oesophageal ulcer with non-specific histology related presumably to reflux. In all cases, the deposits consisted of histiocytes within the lamina propria, in some cases expanding the lamina propria; the histiocytes contained amphophilic granular material, together with coarser brown to deep purple material ( Figure 1 ). The material was refractile but not birefringent under polarized light, indicating amorphous rather than crystalline material. The histiocytes were pale and vaguely epithelioid, but in only one case did they form vaguely rounded aggregates reminiscent of poorly formed granulomas ( Figure 1 ). All cases had at least rare histiocytes that were binucleated or multinucleated. The antral biopsies had either an atrophic appearance or the appearance of reactive gastropathy with foveolar hyperplasia and focal corkscrewing of the pits. The fundic biopsies had less dramatic changes, with foveolar hyperplasia in one case only. The duodenal biopsy showed dramatic expansion of the lamina propria with histiocytes, congestion of the villous tips and focal foveolar metaplasia.
Von Kossa stains were performed in all six biopsies and were negative in all cases. Iron stains were performed on all cases, and in most cases showed faint staining of the largest particles ( Figure 2 ). One case had faint staining of the more fine granular deposits, and one case was negative. Periodic acid-Schiff (PAS) with diastase digestion was performed in two cases and showed faint staining of the granular material. Two cases were assessed with acid-fast and Gomori methenamine silver stains, and were negative. One case was assessed with Fite stain, Brown-Hopps stain, polymerase chain reaction (PCR) for Whipple's disease and immunohistochemistry for Helicobacyer pylori, and these studies were negative.
All cases were signed out initially as non-specific. In several cases a differential was offered of drug ingestion and ingestion of exogenous substances, and in two cases the possibility of infection was also suggested. One pathologist also suggested mucosal calcinosis as a possibility.
On dark-field imaging, the granular material within histiocytes was strongly refractile. SEM/EDS analysis showed that the intracellular deposits contained lanthanum (La), phosphorus (P) and calcium (Ca) ( Figure 3 ). The relative peak heights for La, P and Ca were similar in the three cases, indicating that the deposits are not pure lanthanum phosphate, but a compound that also contains calcium.
Discussion
Hyperphosphataemia is an important risk factor for the development of secondary hyperparathyroidism, metabolic bone disease, vascular calcification and cardiovascular events in patients with chronic renal failure. Consequently, the management of hyperphosphataemia is an important therapeutic target for this patient population. Treatment of high serum phosphorus includes phosphate binders. The utility of aluminum-and calcium-based phosphate binders has been limited by their side-effect profile. Lanthanum carbonate has emerged as a safer calcium-free alternative to traditional phosphate-binding therapies. 4, 12, 13 Lanthanum is a rare alkaline earth metal that binds with phosphate in the GI tract and is excreted mainly in the faeces. 4, 14, 15 Despite a poor absorption rate, lanthanum accumulates in bone, liver, mesenteric lymph nodes and plasma in humans, albeit at low levels. [16] [17] [18] [19] [20] Histological recognition of lanthanum deposition in human tissues was first reported in 2009 in a mesenteric lymph node found during post-mortem examination of a 38-year-old woman with nephrogenic systemic fibrosis (NSF) from gadolinium and endstage renal disease secondary to immunoglobulin (Ig) A nephropathy. 16 Five years later, lanthanum phosphate deposition in GI mucosa was described in a 63-year-old woman with end-stage renal disease, who had undergone peritoneal dialysis and had taken lanthanum carbonate for nearly 4 years. 4 Since then, multiple reports have described lanthanum carbonate deposition in GI biopsies. In a case series of 13 patients, Goto et al. 6 described histological evidence of lanthanum deposition in gastric, duodenal and colonic biopsies in 68% of patients who had taken lanthanum carbonate. Most reported cases, and all the cases in our series, demonstrate lanthanum deposition in the upper GI tract, specifically the stomach. Lanthanum deposition appears as prominent accumulation of histocytes within the lamina propria, just beneath the surface epithelium. [6] [7] [8] 21, 22 The histocytes are filled with material that has been described in various reports as either fine or coarse and ranging from colourless to amphophilic. [6] [7] [8] 21, 22 The lanthanum accumulation within the histocytes has been found to stain positively for PAS, PAS after diastase digestion and, in some cases, Prussian blue. 4, 5 Lanthanum deposition in the upper GI tract may cause a variety of clinical symptoms, including dysphagia, nausea, vomiting and reflux, 5 although these are common and may not be related to the lanthanum. Endoscopic findings are usually nonspecific, as they were in our cases, and include gastritis, gastric erosion, gastric erythema, gastric ulceration, polypoid gastric mucosa and duodenal ulceration. [4] [5] [6] [7] [8] [9] [17] [18] [19] 21, 22 Lanthanum deposition has been detected as early as 3 months after administration. 18 Several reports suggest that the process is reversible after cessation of lanthanum carbonate use. 20 In one case report Rothenberg et al. 8 found that after 3 months of cessation of lanthanum carbonate therapy, there was no histological evidence of lanthanum in the stomach, marked decrease of the histocytosis in the duodenum and resolution of the patient's symptoms, indicating that the lanthanum deposition decreases after cessation of therapy and may be reversible given time. However, there have been experiences that raise questions about the reversibility of lanthanum deposition. Davis and Abraham described persistent granular lanthanum deposition within histiocytes of a mesenteric lymph node of a patient who had not received lanthanum carbonate for 3 years. 16 In our cohort, a 52-year-old man with end-stage renal disease secondary to autosomal dominant polycystic kidney disease was found to have lanthanum deposition in a gastric biopsy 7 years after discontinuation of lanthanum carbonate. The consequences of lanthanum deposition in tissue, particularly the long-term consequences in patients in whom the process does not seem to be reversible, are unknown.
Another rare earth metal that may serve as a cautionary tale is gadolinium, an element used as a contrast agent with magnetic resonance imaging. Gadolinium-containing contrast agents are cleared almost exclusively by the kidney and the half-life increases dramatically with advanced or end-stage kidney disease. 23 With prolonged exposure due to poor renal clearance, gadolinium is deposited in multiple organs, including the skin. [23] [24] [25] [26] Affected individuals develop a debilitating condition known as NSF, where they develop thickened, fibrotic skin which can cause pain and severely restricted mobility. [27] [28] [29] No proven medical therapy exists for NSF, and current practice is to avoid gadolinium exposure in patients with advanced or end-stage kidney disease. Notably, the association between gadolinium exposure and NSF did not come to light until 18 years after gadolinium had been approved by the Food and Drug Administration (FDA). It is also worth noting that the ratios of Gd:P:Ca seen in the insoluble deposits in NSF cases are similar to the La:P:Ca ratios seen in our cases. 30 The presence of histiocytes with granular material within the lamina propria may not be recognized as lanthanum, and none of our cases was recognized initially as being lanthanum deposition. Although the possibility of drug-related GI tract injury was entertained in several cases, there was a broad differential diagnosis and numerous stains were applied in an attempt to define the process. The differential diagnoses of the granular material considered in our series included gastric mucosal calcinosis, iron therapy-induced gastric injury and infection. That some of these deposits stain variably with Prussian blue stain may cause confusion with iron therapy-related gastric injury, although in that condition, the deposits usually appear as yellow-to-brown coarse extracellular deposits in the superficial lamina propria that stain strongly with Prussian blue stain. 31 Interestingly, despite the variable staining with iron stains, EDS did not demonstrate iron, related possibly to the sensitivity of EDS or the state of the iron. Gastric mucosal calcinosis typically shows coarse basophilic deposits in the superficial lamina propria that stain strongly with von Kossa stains for phosphates found in association with the calcium. 32 In conclusion, we believe that lanthanum deposition is readily recognizable by pathologists, once they are aware of the entity. Nephrologists should alert pathologists to the patient's drug history. The identification of lanthanum deposits in these patients may be important, as the long-term consequences of lanthanum in tissue are unknown, the use of this medication is increasing and other options to manage hyperphosphataemia exist in patients with end-stage renal failure. We have also shown that lanthanum deposition may not be reversible in some patients, as evidenced by our transplant patient who had discontinued lanthanum 7 years previously and now has normal renal function. The long-term effects of lanthanum carbonate are still to be determined.
